Voyager Therapeutics (VYGR) Cash & Equivalents (2014 - 2026)

Voyager Therapeutics (VYGR) has 13 years of Cash & Equivalents data on file, last reported at $43.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 42.06% year-over-year to $43.3 million; the trailing twelve-month figure through Mar 2026 stood at $43.3 million (down 42.06% YoY), and the FY2025 full-year result was $65.3 million, down 8.5% from the prior year.
• Cash & Equivalents retreated to $43.3 million in Q1 2026, from $65.3 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $268.3 million in Q1 2023 to a low of $43.3 million in Q1 2026.
• A 5-year average of $101.7 million and a median of $76.1 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents soared 211.88% in 2023 and tumbled 68.84% in 2024, its largest moves.
• Tracing VYGR's Cash & Equivalents over 5 years: stood at $99.0 million in 2022, then sank by 30.47% to $68.8 million in 2023, then grew by 3.73% to $71.4 million in 2024, then decreased by 8.5% to $65.3 million in 2025, then tumbled by 33.67% to $43.3 million in 2026.
• Business Quant data shows VYGR's Cash & Equivalents at $43.3 million in Q1 2026, $65.3 million in Q4 2025, and $45.1 million in Q3 2025.